REVIEW
|
doi:10.20944/preprints202302.0030.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
angiogenesis inhibitors; VEGF inhibitors; ovarian cancer; progression-free survival; overall sur-vival; toxicity; systematic review; meta-analysis; randomized controlled trials; FDA approval of cancer drugs
Online: 2 February 2023 (05:26:47 CET)